Psilocybin Bill: New York, New Jersey, Colorado Webinar Recording
Thank you to everyone who joined our webinar on psilocybin legalization efforts in New York, New Jersey, and Colorado. We had an incredible discussion led by Dr. Hannah McLane and our esteemed panelists: Allison Hoots, Esq., Tasia Poinsatte, Joshua Kappel, Esq., the Honorable Jeannine LaRue, Joseph Shapiro, Esq., Lisa Gora, Esq., and Sara Price, BSN, RN, NC-BC.
Missed the webinar or want to revisit the insights shared? Watch the webinar here:
Experts discussed the current state of psilocybin laws in various states, with a focus on New York, New Jersey, Colorado, and Oregon. They emphasized the importance of navigating concerns around safety, education, and ethics, and highlighted the differences between ballot initiative states and non-ballot initiative states. Panelists also discussed their efforts to legalize psychedelics in these states, including drafting bills and educating local leaders and communities. Additionally, they emphasized the importance of responsible and culturally sensitive approaches to psychedelic healing, including indigenous participation, safety guidelines, and trained facilitation.
Highlights:
Psilocybin laws in New York, New Jersey, Colorado, and Oregon.
Expert panel discusses psilocybin laws in New York, New Jersey, Colorado, and Oregon.
Experts discuss New Jersey's psilocybin legislation at a panel discussion.
New York's psilocybin bill with legal and medical perspectives.
Allison Hoots (attorney and head policy counsel) discussed her experience with psychedelics and drafted Bill 10375 in New York.
Seth Fowler (SoundMind Institute) works with training program and facilitation.
Hannah McLane MD and Allison discuss New York's psilocybin bill, a hybrid model based on existing laws.
Legalizing psilocybin in New York, with focus on education and regulation.
Psilocybin framework prioritizes public health, education, and community well-being.
Licensed cultivators must follow growing conditions, disclosure, labeling, and potency testing for psilocybin.
Allison Hoots explains differences in state legislation processes for medical marijuana bills.
Legalizing psilocybin in New York, with a focus on safety and education.
Allison Hoots highlights the positive aspects of the bill, including the head of the Health Committee as sponsor and educational course requirements.
Allison Hoots expresses optimism about the bill's chances of passing, despite concerns about its likelihood.
Allison Hoots wrote the bill by accident, but with help from many people offering advice and feedback.
New Yorkers for Mental Health Alternatives is a scrappy group working to pass the bill and other mental health-related legislation in New York.
New York state's psilocybin bill and its potential impact.
Allison Hoots discusses the need for education days and a small educational component for New York licensure.
The bill is expected to be reintroduced in September and may take 4 years to pass.
New York has four bills related to psilocybin, each with different approaches and varying levels of progress.
Allison emphasizes the importance of regulating psilocybin for medical use and personal benefit.
New Jersey psilocybin legalization bill with mixed prospects.
Jeannine LaRue, Nick Scutari, and Raj Mukherji sponsored a comprehensive psilocybin bill in New Jersey.
The bill decriminalized psilocybin and allowed for homegrown use, with bipartisan support in both houses.
Jeannine LaRue's clients were invited to testify on a bill, despite initial skepticism from naysayers.
The bill advanced in both the Senate and Assembly committees, despite Republican opposition.
Jeannine LaRue is optimistic about bill's chances despite potential amendments and opposition.
Committee meetings have been positive, with no public opposition, but politics will play a role in final passage.
Lobbying for psilocybin legalization in New Jersey.
Hannah McLane MD testifies on medical marijuana in New Jersey, highlighting its potential as a non-ballot initiative state.
Jeannine LaRue shares her experience with lobbying, mentioning her sister who became a lawyer and their own path to becoming an English teacher before starting lobbying.
Hannah McLane MD provides insight into the role of lobbyists, explaining that they are not all lawyers and that lobbying involves advocating for specific issues or policies.
Jeaninne: Lobbying in NJ requires registration for more than 20 hours of work per year on any issue.
Jeaninne: Dealing with coalitions of folks makes it easier to write comprehensive bills on controversial issues.
New Jersey's psilocybin bill, focusing on its medicalization and regulation.
Lisa Gora highlights the political significance of the bill, citing the need for access to effective and safer treatments.
The bill seeks to improve physical, mental, and social well-being in New Jersey, and prevent behavioral health disorders.
New Jersey proposes medical model for psilocybin treatment, including licensed service centers.
NJ psilocybin service center regulations.
Advisory Board to develop application process for psilocybin service centers.
Licensed practitioners in NJ must determine if patients have qualifying conditions for psilocybin therapy.
Patients must receive referral from licensed practitioner and confirmation from village service center.
The psilocybin service center verifies patient information and conducts safety screenings before providing informed consent.
The administration session lasts between 2-6 hours, with a licensed facilitator guiding the patient through the experience.
NJ psilocybin bill, including referral requirements and municipal concerns.
Hannah McLane MD and Lisa Gora discuss qualifications for psilocybin treatment in NJ, including mental health conditions and potential for physical ailments.
New Jersey aims to integrate medical and non-medical models in psychedelic law.
Joseph Shapiro discusses potential issues with medicalization of psilocybin in Oregon, including educating towns about the legislation and addressing advertising and housing constraints.
Joseph Shapiro emphasizes the importance of paying attention to municipal-level implications of the bill, especially with New Jersey's cannabis legislation in mind.
Advocating for psychedelic decriminalization in New Jersey, with a focus on personal stories and local leadership.
Sara Price shares personal story to humanize data and build empathy with local leaders.
Speakers discuss ways to involve community in psychedelic decriminalization efforts in New Jersey.
Psychedelic access and affordability in various states.
Hannah McLane MD highlights the potential for mushroom-grown psychedelics to provide more affordable access to mental health treatments, as opposed to pharmaceutical companies.
Speakers discuss the opportunities for flexibility in group settings and different ways to make sessions more accessible, such as sliding scale fees or free sessions.
Hannah McLane handled testimony well, responded positively to legislators' questions.
New Jersey, Colorado, and other states need help passing mental health legislation.
Colorado's National Mental Health Act, including decriminalization of psilocybin and other psychedelics, regulatory model, civil
Joshua Kappel and Tasia Poinsatte are working on implementing Colorado's National Mental Health Act, which decriminalizes certain psychedelics and provides civil protections for their use.
Tasia Poinsatte's main role is working on the what comes after portion of the process, addressing questions and concerns that arise after the bill is passed.
Colorado's psilocybin program requires facilitators to hold a clip clinical license or a facilitator license, with different requirements for each type.
Training requirements are more robust than in Oregon, with additional consultation and location-specific requirements still being developed.
Psychedelic decriminalization and regulation in Colorado, with a focus on indigenous involvement and safety guidelines.
Joshua Kappel explains Colorado's new licensing pathways for facilitators, including a training license pathway and a portable Oregon license pathway.
Legacy facilitators can waive training requirements if they can prove 200 hours of facilitation experience over 2 years, and then take an ethics course.
Lisa Gora discusses Colorado's decriminalization of psilocybin mushrooms and Ibogaine, with the latter being the only one not included in the sharing.
Indigenous participation in the process is a significant aspect of Colorado's legalization efforts, with a working group focused on avoiding misappropriation of indigenous cultures and traditions.
Lisa Gora emphasizes the importance of respecting indigenous cultures and obtaining informed consent when working with traditional medicines.
Hannah McLane MD (SoundMind) highlights the need for safety guidelines and responsible commercialization of these medicines.
Safety and accessibility in psychedelic therapy.
Joshua Kappel advocates for smaller healing centers to have carve-outs in regulations to avoid expensive security systems.
Joshua Kappel suggests treating psychedelic care as one modality of healing, allowing for multi-use premises and multiple modalities of care.
Safety screen for facilitators to assess participants' risk and ensure accessibility (Joshua Kappel)
Limited data on excluded conditions and medications in clinical trials (Lisa Gora)
Lisa Gora emphasizes importance of proper training for facilitators.
Facilitator training crucial for participant safety and informed consent.
Psilocybin therapy for mental health, with focus on residency requirements in New Jersey.
Psilocybin therapy may destabilize individuals with pre-existing heart conditions, requiring screening and backup plans.
Panelists discuss potential for New Jersey to set precedent for East Coast cannabis legalization.
Legalizing psychedelics, potential impact on municipal resources, and funding for program.
Jeannine LaRue argues that psilocybin legalization will not generate significant revenue for municipalities, but may reduce strain on resources.
Joseph Shapiro suggests that instead of focusing on potential revenue, the conversation should shift to how psilocybin can improve public health and reduce strain on municipal resources.
Jeannine LaRue expresses confusion over lack of funding details in New Jersey cannabis bill.
Decriminalizing psilocybin in New Jersey.
The company is developing a psilocybin-based therapy for depression, with a focus on safety and realism.
The therapy will be delivered directly to patients' homes to avoid zoning issues and complications.
Allison Hoots discusses Oregon Measure 110, which decriminalized opioids and psilocybin, but was repealed due to the opioid epidemic.
Sara Price thanks Allison for her work on the bill, which could lead to sovereign use of psilocybin in the future.
Lisa Gora explains personal use limits for cannabis in New Jersey, including possession and cultivation limits.
Jeannine LaRue shares their experience advocating for cannabis legalization in New Jersey, highlighting progress made despite initial skepticism.
Legalizing psychedelics in three US states with panelists sharing insights and final thoughts.
Hannah McLane and panelists discuss legalized psychedelic frameworks in three US states.
Josh encourages listeners to get involved in shaping the psychedelic space.
Hannah McLane leads another short breathwork session.